Please select the eligibility criteria that correspond to the clinical trial below.
Title: Wiser Choices In Osteoporosis Choice II
Brief Summary: Emphasis in treating osteoporosis has been on T-scores rather than overall fracture risk. Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis treatment by providing an absolute fracture risk. FRAX combined with a decision aid may promote a shared decision making approach with patients, allowing the clinician and patient to weigh potential fracture risk (without treatment), versus risk reduction with medication (including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:

* FRAX
* FRAX + decision aid
* Usual care (no decision aid and no FRAX given to clinician)


Options:
A: Inclusion Criteria:

* Established patients
* Men ages 35-79
* Women ages 45-79
* History of CVD (100 participants)
* CHD risk equal or greater than 10%
* elevated CHD risk factor

Exclusion Criteria:

* non-English speaking
* no phone
* treatment of psychosis
* history of alcohol/substance abuse within last 2 years
* pregnancy, breast feeding, or anticipated pregnancy in next 18 months
* history of malignancy, other than non-melanoma skin cancer, that has not been in remission or cured surgically for \>5 years
* recent history (in past year) of hypoglycemic event requiring medical attention
* estimated creatinine clearance less than 30 ml/min
B: Patient or family member meeting 1 of the following revised Bethesda colorectal cancer (CRC) criteria:

* Diagnosis of colon or rectal cancer at \< 50 years of age
* Diagnosis of \> 1 CRC at one time in the past
* Diagnosis of ≥ 1 CRC at different times
* Diagnosis of CRC and any other hereditary nonpolyposis colorectal cancer (HNPCC)-related cancers
* Diagnosis of CRC in ≥ 2 first-degree or second-degree relatives with HNPCC-related tumor and ≥ 1 cancer diagnosed at \< 50 years of age
* Diagnosis of CRC in ≥ 2 first- or second-degree relatives with HNPCC-related tumors, regardless of age
* Diagnosis of CRC with pathologic features suggestive of microsatellite instability (MSI) and \< 60 years of age

  * Patients with CRC meeting the Amsterdam criteria defined below are ineligible:
* Three relatives with CRC with 1 being a first-degree relative of the other 2
* Cases that span ≥ 2 generations
* At least 1 CRC case diagnosed before 50 years of age

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified
C: Inclusion Criteria:

Each subject must meet the following inclusion criteria to be enrolled:

1. Participant must be 18-74 years of age.
2. Participant must self-identify as African American or White.
3. Participant must currently be on dialysis.
4. Participant must have a household income at or below 250% of the federal poverty level.
5. Participant must be able to speak and read in English.

Exclusion Criteria:

Subjects that meet any of the following exclusion criteria are not to be enrolled:

1. Participant has a visual and/or hearing impairment that would preclude him/her from watching and reading educational study material.
2. Participant has had a previous kidney transplant
3. Participant has previously been told that they are not a candidate for transplant.
D: Inclusion Criteria:

* Peri and Postmenopausal Caucasian, Black, Hispanic and Asian women, aged 50-90
* Bone mineral density (BMD) T-Score \< 1.0
* Have appointment with clinician to discuss test results and treatment options
* Patients with FRAX \<20% risk who have taken a bisphosphonate for \< 5 years.

Exclusion Criteria:

* Unable to speak or read English

Answer: D